Solid Biosciences Inc.
SLDB Nasdaq
SEC CIK 1707502
Follow Solid Biosciences
Weekly email: filings, results
Net income
−$53.9M
−17.9% vs same quarter last year
EPS, diluted
−$0.36
+25% vs same quarter last year
Operating cash flow
−$45.5M
−36.1% vs same quarter last year
Operating income
−$57.7M
−20% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$174.3M |
| FY24 | - | −$124.7M |
| FY23 | - | −$96M |
| FY22 | $8.1M | −$86M |
| FY21 | $13.6M | −$72.2M |
| FY20 | $0 | −$88.3M |
| FY19 | $0 | −$117.2M |
| FY18 | $0 | −$74.8M |
| FY17 | $0 | −$52.1M |
| FY16 | $0 | −$21.5M |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$157.4M |
| FY24 | −$100.7M |
| FY23 | −$95.7M |
| FY22 | −$101M |
| FY21 | −$79M |
| FY20 | −$57.5M |
| FY19 | −$97.1M |
| FY18 | −$78M |
| FY17 | −$45.5M |
| FY16 | −$20.5M |